Gene editing has been a research goal ever since scientists came to understand that DNA carried heritable information. Gene manipulation through recombinant DNA techniques is not editing, unless your idea of editing is to rip a page from book, trim it and photocopy it, then bomb a print works with the copies and hope one becomes inserted into another book in a place that makes sense. Real gene editing had to wait until 2012, when scientists at the University California, Berkeley developed a method directly equivalent to red-line deletion or insertion of text. This was CRISPR (pronounced "crisper"), a method in which the snipping out and splicing in of DNA takes place in situ, within the organism.
Scrip's Rough Guide To CRISPR Gene Editing
CRISPR technology was invented less than four years ago but is so accurate, versatile, easy to use, and inexpensive that it has spread quickly through biology laboratories, transforming the way gene editing is done and offering its potential use in a wide array of therapies. Here Scrip tells you all you need to know about this disruptive technology.

More from Business
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
More from Scrip
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.